Date: 2016-04-29
Type of information: Milestone
Compound:
Company: Ablynx (Belgium) Novartis (Switlzerland)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: In December 2005, Ablynx and Novartis entered into an agreement to discover and develop novel Nanobody-based therapeutics against a number of disease targets. The deal included R&D payments, license fees, milestones and royalties. Novartis has full responsibility for the development and commercialisation and Ablynx is eligible to receive development and regulatory milestone payments and royalties on sales following commercialisation of the related products.
Financial terms:
Latest news: * On April 29, 2016, Ablynx announced that it has received an undisclosed milestone payment from its collaboration with Novartis. The payment was triggered by the clearance of the Investigational New Drug (IND) application by the FDA for the Novartis Phase I study with a Nanobody that binds with an undisclosed GPCR target in inflammation. The Phase I study is expected to start in Q2 2016.
